Apyx Medical (APYX) 10-Q 15 Nov 19 2019 Q3 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	9 Months Ended
	Sep. 30, 2019	Nov. 11, 2019
Document And Entity Information
Entity Registrant Name	APYX MEDICAL CORP
Entity Central Index Key	0000719135
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,168,230
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 62,272	$ 16,466
Short term investments	0	61,678
Trade accounts receivable, net of allowance of $354 and $428	7,662	5,015
Inventories, net of provision for obsolescence of $439 and $439	7,237	5,212
Prepaid expenses and other current assets	1,734	1,146
Total current assets	78,905	89,517
Property and equipment, net	6,645	5,788
Operating lease right-of-use assets	368
Finance lease right-of-use assets	638
Other assets	387	305
Total assets	86,943	95,610
Current liabilities:
Accounts payable	1,457	1,423
Accrued expenses and other liabilities	7,285	6,162
Current portion of operating lease liabilities	101
Current portion of finance lease liabilities	196
Total current liabilities	9,039	7,585
Note payable	140	140
Long-term operating lease liabilities	248
Long-term finance lease liabilities	444
Contract liabilities	339	0
Total liabilities	10,210	7,725
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,120,065 issued and 33,977,490 outstanding as of September 30, 2019, and 33,847,100 issued and 33,704,525 outstanding as of December 31, 2018	34	34
Additional paid-in capital	55,668	52,920
Retained earnings	21,031	34,931
Accumulated other comprehensive income, net of tax:	76,733	87,885
Foreign currency translation adjustment	$ 86,943	$ 95,610

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 354	$ 428
Inventories, provision for obsolescence	$ 439	$ 439
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	34,120,065	33,847,100
Common stock, shares outstanding (in shares)	33,977,490	33,704,525

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Sales	$ 7,575	$ 3,672	$ 19,772	$ 10,760
Cost of sales	2,558	1,151	6,757	3,490
Gross profit	5,017	2,521	13,015	7,270
Other costs and expenses:
Research and development	936	613	2,634	1,890
Professional services	1,996	628	5,756	1,815
Salaries and related costs	3,020	2,119	9,691	5,734
Selling, general and administrative	3,762	1,957	9,869	6,280
Total other costs and expenses	9,714	5,317	27,950	15,719
Loss from operations	(4,697)	(2,796)	(14,935)	(8,449)
Interest income	327	135	1,153	135
Interest expense	0	(30)	0	(102)
Other income (losses), net	230	(155)	5	(155)
Change in value of derivative liabilities	0	0	0	20
Total other income (expense), net	557	(50)	1,158	(102)
Loss before income taxes	(4,140)	(2,846)	(13,777)	(8,551)
Income tax expense (benefit)	171	(2,408)	123	(2,384)
Loss from continuing operations	(4,311)	(438)	(13,900)	(6,167)
Income from discontinued operations, net of tax	0	540	0	5,062
Gain on sale of Core Business, net of tax	0	69,072	0	69,072
Total income from discontinued operations, net of tax	0	69,612	0	74,134
Net income (loss)	$ (4,311)	$ 69,174	$ (13,900)	$ 67,967
EPS from continuing operations:
Basic and diluted (in dollars per share)	$ (0.13)	$ (0.01)	$ (0.41)	$ (0.19)
EPS from discontinued operations:
Basic (in dollars per share)	0	2.09	0	2.25
Diluted (in dollars per share)	0	1.99	0	2.19
EPS from total operations:
Basic (in dollars per share)	(0.13)	2.08	(0.41)	2.06
Diluted (in dollars per share)	$ (0.13)	$ 1.98	$ (0.41)	$ 2

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated deficit)
Beginning balance (in shares) at Dec. 31, 2017		32,878,000
Beginning balance at Dec. 31, 2017	$ 22,032	$ 33	$ 50,495	$ (28,496)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)		28,000
Options exercised	65		65
Stock based compensation	1,238		1,238
Shares issued on net settlement of warrants (in shares)		17,000
Shares issued on net settlement of warrants	$ 0
Shares issued on net settlement of stock options (in shares)	713,980	697,000
Shares issued on net settlement of stock options	$ 0
Net income (loss)	67,967			67,967
Ending balance (in shares) at Sep. 30, 2018		33,620,000
Ending balance at Sep. 30, 2018	91,302	$ 33	51,798	39,471
Beginning balance (in shares) at Jun. 30, 2018		32,913,000
Beginning balance at Jun. 30, 2018	21,574	$ 33	51,244	(29,703)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)		28,000
Options exercised	65		65
Stock based compensation	$ 489		489
Shares issued on net settlement of stock options (in shares)	680,388	679,000
Shares issued on net settlement of stock options	$ 0
Net income (loss)	69,174			69,174
Ending balance (in shares) at Sep. 30, 2018		33,620,000
Ending balance at Sep. 30, 2018	91,302	$ 33	51,798	39,471
Beginning balance (in shares) at Dec. 31, 2018		33,705,000
Beginning balance at Dec. 31, 2018	87,885	$ 34	52,920	34,931
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)		51,000
Options exercised	154		154
Stock based compensation	$ 2,594		2,594
Shares issued on net settlement of stock options (in shares)	220,879	221,000
Shares issued on net settlement of stock options	$ 0
Net income (loss)	(13,900)			(13,900)
Ending balance (in shares) at Sep. 30, 2019		33,977,000
Ending balance at Sep. 30, 2019	76,733	$ 34	55,668	21,031
Beginning balance (in shares) at Jun. 30, 2019		33,921,000
Beginning balance at Jun. 30, 2019	80,462	$ 34	55,086	25,342
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)		21,000
Options exercised	39		39
Stock based compensation	$ 543		543
Shares issued on net settlement of stock options (in shares)	34,928	35,000
Shares issued on net settlement of stock options	$ 0
Net income (loss)	(4,311)			(4,311)
Ending balance (in shares) at Sep. 30, 2019		33,977,000
Ending balance at Sep. 30, 2019	$ 76,733	$ 34	$ 55,668	$ 21,031

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (13,900)	$ 67,967
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of the Core Business, net of tax	0	(69,072)
Depreciation and amortization	510	429
Provision for inventory obsolescence	115	0
Unrealized gain on foreign currency remeasurement	(12)	0
Loss on disposal of property and equipment	19	0
Stock based compensation	2,594	1,238
Change in fair value of derivative liabilities	0	(20)
Net, non cash lease expense	2
Realized and unrealized gains on short term investments	(164)	(47)
Provision for allowance for doubtful accounts	(94)	123
Benefit of deferred taxes	0	(368)
Changes in operating assets and liabilities:
Trade receivables	(2,580)	654
Prepaid expenses	(596)	(188)
Inventories	(2,463)	(1,706)
Deposits and other assets	(131)	(9)
Accounts payable	50	765
Accrued and other liabilities	1,556	(2,601)
Net cash used in operating activities	(15,094)	(2,835)
Cash flows from investing activities
Purchases of property and equipment	(1,076)	(203)
Purchases of marketable securities	(18,884)	(55,433)
Proceeds from maturities of marketable securities	80,726	0
Proceeds from the disposition of Core business	0	91,095
Net cash provided by investing activities	60,766	35,459
Cash flows from financing activities
Proceeds from stock options	154	65
Repayment of finance lease liabilities	(2)	0
Repayment of mortgage note payable	0	(2,694)
Net cash provided by (used in) financing activities	152	(2,629)
Effect of foreign currency translation on cash	(18)	0
Net change in cash, cash equivalents and restricted cash	45,806	29,995
Cash, cash equivalents and restricted cash, beginning of period	16,466	10,668
Cash, cash equivalents and restricted cash, end of period	62,272	40,663
Cash paid for:
Interest	0	102
Non cash financing activities:
Cashless exercise of stock options/warrants	$ 957	$ 3,133

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Unless the context otherwise indicates, the terms “Company,” “we,” “our,” “us,” “Apyx,” and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries. We are a medical technology company and the developer of J-Plasma ® (marketed and sold under the Renuvion ® Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma ® technology utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision and minimal invasiveness. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. On August 30, 2018, we closed on a definitive A sset P urchase A greement with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which we divested and sold our electrosurgical "Core" business segment and related intellectual property, including the Bovie ® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. The divestiture and sale of our Core business segment to Symmetry allows us to further focus on our strategic objective of commercializing our J-Plasma ® technology, including the Renuvion ® brand in the cosmetic surgery market. We also entered into with Symmetry a T ransition S ervices A greement, a Patent Licensing Agreement, a Disposables Supply Agreement, and a Generator Manufacturing and Supply Agreement, the latter of which will establish us as an OEM-provider of generators to Symmetry for a period of at least 10 years from the agreement date . In connection with the A sset P urchase A greement, we also entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for up to a four -year term, whereby we will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any revenue, costs and expenses resulting from this agreement are netted and reported in our c onsolidated s tatements of o perations as o ther gains or losses. For the three months ended September 30, 2019, Core sales following the divestiture amounted to $2.5 million with cost of sales of $2.1 million and related operating expenses of $0.2 million , which are included in other income ( losses ) i n the c onsolidated s tatement s of o perations. For the nine months ended September 30, 2019, Core sales following the divestiture amounted to $6.9 million with cost of sales of $6.6 million and related operating expenses of $0.3 million , which are included in other income ( losses ) in the c onsolidated s tatement s of o perations. In connection with the A sset P urchase A greement, we also entered into a Manufacture and Supply Agreement with Symmetry for a ten -year term, whereby we will manufacture certain products and sell them to Symmetry at agreed upon prices. Revenue, costs and expenses resulting from this agreement are reported in our c onsolidated s tatements as income or loss from operations of our OEM reporting segment. We reclassified the financial results of the Core business to discontinued operations and from segment results for all periods presented. Revisions Throughout 2019, the Company has been making efforts to remediate its material weakness in internal control as of December 31, 2018, including investing in new personnel that have expertise in a broad array of accounting topics. As a result of these investments, the Company reevaluated its accounting for stock-based compensation expense and during the three months ended September 30, 2019, the Company discovered immaterial errors in its accounting for certain items included in stock-based compensation expense. These errors related to its accounting for forfeitures, the vesting periods over which the expense was recognized, modifications, fair value measurements, and other minor miscellaneous items, all of which relate to the prior year. Additionally, the Company identified an issue relating to grants in the first quarter of 2019, whereby compensation was not recognized over the correct vesting period. During the three months ended September 30, 2019, the Company re-evaluated its accounting for pre-development activities on certain OEM contracts. In performing the review, the Company determined that the it has not completed its performance obligations on its pre-development activities in these contracts. Accordingly, the Company determined that it had prematurely recognized revenues during the first quarter relating to these activities and did not defer the accompanying costs. The Company has determined that the effects of the corrections are not material to the consolidated financial statements as of December 31, 2018, March 31, 2019 or June 30, 2019, but has elected to correct the consolidated financial statements for the three and nine months ended September 30, 2019. Accordingly, the Company has corrected the errors in the periods to which they relate. There were no adjustments to the results of operations for the three months ended June 30, 2019. A summary of the revisions as of each reporting period affected is as follows: As of and for the year ended December 31, 2018: (In thousands) As Reported Adjustments As Revised Balance Sheet Accrued severance and related $ 727 $ (117 ) $ 610 [1], [3] Additional paid-in capital 52,221 699 52,920 [1] Retained earnings 35,513 (582 ) 34,931 [1] Statement of Operations Professional services $ 3,072 $ 34 $ 3,106 [1] Salaries and related costs 8,673 548 9,221 [1] Loss per share from continuing operations Basic and Diluted $ (0.29 ) $ (0.01 ) $ (0.30 ) Income per share from discontinued operations Basic $ 2.21 $ — $ 2.21 Diluted $ 2.14 $ — $ 2.14 Income per share all operations Basic $ 1.93 $ (0.02 ) $ 1.91 Diluted $ 1.86 $ (0.01 ) $ 1.85 [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction [3] Financial statement caption has been condensed in accrued expenses and other liabilities in the current interim period As of and for the three months ended March 31, 2019: (In thousands) As Reported Adjustments As Revised Balance Sheet Other assets $ 162 $ 77 $ 239 [1] Contract liabilities — 194 194 [1] Additional paid-in capital 53,147 1,035 54,182 [1] Retained earnings 30,832 (1,152 ) 29,680 [1] Statement of Operations Sales $ 5,823 $ (194 ) $ 5,629 [2] Professional services 1,791 336 2,127 [1] Salaries and related costs 3,221 117 3,338 [1] Selling, general and administrative 3,101 (77 ) 3,024 [2] Loss per share - basic and diluted $ (0.14 ) $ (0.02 ) $ (0.16 ) [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction As of and for the six months ended June 30, 2019: (In thousands) As Reported Adjustments As Revised Balance Sheet Other assets $ 368 $ 77 $ 445 [1] Contract liabilities — 194 194 [1] Additional paid-in capital 54,051 1,035 55,086 [1] Retained earnings 26,494 (1,152 ) 25,342 [1] Statement of Operations Sales $ 12,391 $ (194 ) $ 12,197 [2] Professional services 3,424 336 3,760 [1] Salaries and related costs 6,554 117 6,671 [1] Selling, general and administrative 6,184 (77 ) 6,107 [2] Loss per share - basic and diluted $ (0.27 ) $ (0.02 ) $ (0.29 ) [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 . These consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 6,126 $ 4,521 Finished goods and work-in-process 1,550 1,130 Gross inventories 7,676 5,651 Less: reserve for obsolescence (439 ) (439 ) Net inventories $ 7,237 $ 5,212

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILTIES (Notes)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILTIES Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, 2019 December 31, 2018 Accrued severance and related $ 235 $ 610 Accrued payroll 289 418 Accrued bonuses 936 972 Accrued commissions 784 379 Accrued legal and insurance 1,649 725 Other accrued expenses and current liabilities 3,392 3,058 Total accrued expenses and other current liabilities $ 7,285 $ 6,162

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment will not have a material impact on our consolidated financial condition or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Topic 842 establishes a new lease model, referred to as the right-of-use model that brings substantially all leases on the balance sheet. This standard requires lessees to recognize leased assets and lease liabilities on the balance sheet and disclose key information about the leasing arrangements in their financial statements. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted Topic 842 effective January 1, 2019 using the modified retrospective transition approach that allows a reporting entity to use the effective date as its date of initial application and not restate the comparative periods in the period of adoption when transitioning to the new standard. Consequently, the requisite financial information and disclosures under the new standard are excluded for dates and periods prior to January 1, 2019. In addition, the Company elected to use a number of optional simplification and practical expedients permitted under the transition guidance within the new standard, including allowing the Company to combine fixed lease and non-lease components, apply the short-term lease exception to all leases of one year or less, and utilize the ‘package of practical expedients’, which permits the Company to not reassess prior accounting conclusions with respect to lease identification, lease classification and initial direct costs under Topic 842. Adoption of this new standard resulted in the recognition of approximately $212,000 of operating lease liabilities and right-of-user assets, which represents the present value of the remaining lease payments at the adoption date of approximately $221,000 , discounted using the Company’s incremental borrowing rate of 4.00% . Please see Note 13 for a full discussion of the impacts of adoption on the current year consolidated financial statements. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE We compute basic earnings per share (“basic EPS”) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS . Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. The following table provides the computation of basic and diluted earnings per share. Three Months Ended September, 30 Nine Months Ended (in thousands, except per share data) 2019 2018 2019 2018 Numerator: Net loss from continuing operations $ (4,311 ) $ (438 ) $ (13,900 ) $ (6,167 ) Net income from discontinued operations, net of tax $ — $ 69,612 $ — $ 74,134 Net income (loss) from all operations $ (4,311 ) $ 69,174 $ (13,900 ) $ 67,967 Denominator: Denominator - basic Weighted average shares outstanding - basic 33,942 33,275 33,903 33,014 Contingently issuable shares - basic 136 — 136 — Denominator - basic and diluted from continuing operations 34,078 33,275 34,039 33,014 Effect of dilutive securities: Stock options — 1,659 — 938 Denominator - diluted discontinued and all operations : 34,078 34,934 34,039 33,952 Loss per share from continuing operations: Basic and diluted $ (0.13 ) $ (0.01 ) $ (0.41 ) $ (0.19 ) Income per share from discontinued operations Basic $ — $ 2.09 $ — $ 2.25 Diluted $ — $ 1.99 $ — $ 2.19 Income (loss) per share from all operations Basic $ (0.13 ) $ 2.08 $ (0.41 ) $ 2.06 Diluted $ (0.13 ) $ 1.98 $ (0.41 ) $ 2.00 Anti-dilutive instruments excluded from diluted loss per common share: Restricted stock 90 — 90 — Options 4,060 — 4,060 —

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our key employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense amortized over the vesting period based on the trinomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense. In September 2019, the Company registered 2,000,000 shares under our shareholder approved 2019 Share Incentive Plan. We recognized approximately $543,000 and $2,594,000 in stock-based compensation expense during the three and nine months ended September 30, 2019 , respectively, as compared with $489,000 and $1,238,000 for the three and nine months ended September 30, 2018 , respectively . The status of our stock options are summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2018 3,254,779 $ 3.18 Granted 1,379,500 7.70 Exercised (391,135 ) 2.84 Canceled and forfeited (183,500 ) 3.41 Outstanding at September 30, 2019 4,059,643 $ 4.73 The Company allows employees to exercise stock-based awards by surrendering stock-based awards with a fair value of the stock-based awards exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2019 and 2018, respectively, the Company received 26,572 and 532,477 options as payment in the exercise of 34,928 and 680,388 options. For the nine months ended September 30, 2019 and 2018, respectively, the Company received 118,170 and 576,135 options and warrants as payment in the exercise of 220,879 and 713,980 options and warrants. Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. We calculated the fair value of issued options utilizing a trinomial lattice with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life. 2019 Grants Option value $ 7.15 - $ 7.91 Risk-free rate 1.7% - 2.6 % Expected dividend yield — Expected volatility 67.6% - 69.1 % Expected term (in years) 6 During September 2019, the Company determined that it had classified grants of 225,922 in restricted stock as stock options in the consolidated financial statements since the grant date. At September 30, 2019, 135,555 of the shares had vested, with the remaining shares vesting through October 2021. At September 30, 2019, the Company has approximately $94,000 of stock-based compensation expense to be recognized through October 2021.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s income tax expense from continuing operations was approximately $171,000 and $123,000 with an effective tax rate of (4.1)% and (0.9)% for the three and nine months ended September 30, 2019, respectively, as compared to a benefit of approximately $ 2,400,000 , and $2,400,000 with an effective tax rate of 84.6% and 27.9% , for the three and nine months ended September 30, 2018, respectively. The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended September 30, 2019. (in thousands) Gross Unrealized Tax Benefits Balance at January 1, 2019 $ 1,313 Additions of tax positions related to the current year — Additions of tax positions related to the prior year — Decreases for tax positions related to the prior year — Balance at September 30, 2019 $ 1,313 The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the Company’s condensed consolidated financial statements. As of September 30, 2019, the Company had approximately $197,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three and nine months ended September 30, 2019 are approximately $146,000 and $197,000 , respectively, of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,510,000 of tax benefits in the provision of income taxes. It is expected that all of the uncertain tax positions should be resolved by October 2022 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims. We are involved in a number of legal actions relating to the use of our J-Plasma® technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows. In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Report on Form 8-K filed April 26, 2019, on April 17, 2019, a complaint (the “Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff Kyle Pritchard, individually and on behalf of all others similarly situated against the Company and Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended. On July 16, 2019, the Court appointed a lead plaintiff for the putative class and approved the lead plaintiff’s selection of counsel. On or about September 3, 2019, Plaintiff filed an amended complaint (the “Amended Complaint”) with the Court. The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company’s securities between December 21, 2018 and April 1, 2019 and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company’s J-Plasma® technology for use in dermal resurfacing procedures. The Amended Complaint seeks an unspecified amount of compensatory damages, an award of interest, reasonable attorneys’ fees, expert fees and other costs, and equitable relief as the court may deem just and proper. On October 3, 2019, the Company and Goodwin filed a Motion to Dismiss the Amended Complaint. Plaintiff’s opposition to the motion to dismiss was served on November 4, 2019. Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Amended Complaint are entirely without merit. The Company and Goodwin intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated earnings, financial position or cash flows. Under the deductible portion of our insurance coverage, we have accrued $500,000 for initial defense costs. W e accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates. Purchase Commitments At September 30, 2019 , we had purchase commitments totaling approximately $4,600,000 , substantially all of which is expected to be purchased within the next six months . In response to the current worldwide helium shortage, to support our current and near term customer requirements, we issued purchase orders with two international companies to supply us with helium cylinders and have entered into agreements to purchase additional helium as needed. We also currently maintain our own supply of helium in the United States , which can be utilized for our customer requirements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the a ccounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev’s sister, is the m anager of p roduction and h uman r esources. Svetoslav Shilev, Mr. Shilev’s son, is an e ngineer in the q uality a ssurance department. In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $140,000 to be paid 5 years after the original purchase date , which is in October 2020.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS Cash, Cash Equivalents and Marketable Securities at September 30, 2019, consists of approximately $1,300,000 in cash and $61,000,000 in US Treasury Securities with maturities of 3 months or less. Cash, Cash Equivalents and Marketable Securities at December 31, 2018: (In thousands) Adjusted Cost Unrealized Gains Fair Value (3) Cash and Cash Equivalents (1) Short-term Marketable Securities Cash $ 6,337 $ — $ 6,337 $ 6,337 $ — Level 1 (2) U.S. Treasury Securities, maturities less than three months 10,129 — 10,129 10,129 — U.S. Treasury Securities, maturities greater than three months 61,431 247 61,678 — 61,678 Total $ 77,897 $ 247 $ 78,144 $ 16,466 $ 61,678 (1) The Company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents. (2) The fair value of the debt securities consisting of U.S. Treasury bills is based on their quoted market prices. The fair value of these financial instruments are classified as Level 1 in the fair value hierarchy. The original purchase of U.S. Treasury bills occurred in September 2018, utilizing the proceeds from the sale of our Core business. (3) ASC 825-10 , Financial Instruments , allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings within interest income at each subsequent reporting date. At the date of purchase, the Company elected the fair value option for all investments with maturities of three months or greater at the time of purchase.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. Net assets are shared, therefore, not allocated to the reportable segments. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2019 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 6,094 $ 1,481 $ — $ 7,575 Income (loss) from continuing operations (1,357 ) 268 (3,608 ) (4,697 ) Interest income — — 327 327 Other income, net — — 230 230 Income tax expense — — (171 ) (171 ) Three Months Ended September 30, 2018 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,985 $ 687 $ — $ 3,672 Income (loss) from continuing operations (1,155 ) 368 (2,009 ) (2,796 ) Interest income, net — — 105 105 Income tax benefit — — 2,408 2,408 Nine Months Ended September 30, 2019 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 15,734 $ 4,038 $ — $ 19,772 Income (loss) from continuing operations (5,756 ) 995 (10,174 ) (14,935 ) Interest income — — 1,153 1,153 Other income, net — — 5 5 Income tax expense — — (123 ) (123 ) Nine Months Ended September 30, 2018 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,727 $ 2,033 $ — $ 10,760 Income (loss) from continuing operations (2,525 ) 1,076 (7,000 ) (8,449 ) Interest income, net — — 33 33 Change in value of derivative liabilities — — 20 20 Income tax benefit — — 2,384 2,384 International sales represented approximately 26.7% of total revenues for the three months ended September 30, 2019, as compared with 24.8% of total revenues for the same prior year period. International sales represented approximately 29.2% of total revenues for the nine months ended September 30, 2019 , as compared with 21.2% of total revenues for the same prior year period. Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2019 2018 2019 2018 Sales by Domestic and International Domestic $ 5,552 $ 2,763 $ 14,002 $ 8,481 International 2,023 909 5,770 2,279 Total $ 7,575 $ 3,672 $ 19,772 $ 10,760

FOREIGN CURRENCY TRANSACTIONS

FOREIGN CURRENCY TRANSACTIONS	9 Months Ended
	Sep. 30, 2019
Foreign Currency Transaction [Abstract]
FOREIGN CURRENCY TRANSACTIONS	FOREIGN CURRENCY TRANSACTIONS The functional currency of Apyx Bulgaria is the U.S. dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar of Apyx Bulgaria are remeasured into U.S. dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the consolidated statements of operations and were not material for the three and nine months ended September 30, 2019.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
LEASES	LEASES The Company does not recognize leases with terms less than twelve months in duration in our consolidated balance sheet as right-of-use assets and lease liabilities. Leases with an initial term of 12 months or less or that have variable only payments are not recorded on the balance sheet. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's leases and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes a incremental borrowing rate of 4.00% , which is indicative of our collateralized borrowing rate. Operating Leases The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During Q2 2019, the Bulgaria facility lease was extended for an additional 2 years . In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. The Company's operating leases have terms expiring through December 2022. Finance Leases During August 2019, the Company entered into a non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. The Company's finance leases have terms expiring through August 2023. Information about the Company’s lease costs are as follows: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Lease costs (in thousands) : Operating lease costs $ 30 $ 85 Finance lease costs: Amortization of right-of-use assets 4 4 Interest on lease liabilities — — Variable lease costs 5 11 Total lease costs $ 39 $ 100 Cash and non cash information related to our leases are as follows: Nine Months Ended September 30, 2019 (in thousands) Operating Finance Non cash information: Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842 $ 212 $ — Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement $ 207 $ — Right-of-use assets capitalized and lease liabilities recognized upon execution of lease $ 20 $ 642 Cash information: Cash paid for lease liabilities $ 85 $ 12 Net, non cash lease expense of $2,000 for the nine months ended September 30, 2019 is comprised of reductions of operating right-of-use assets of $78,000 partially offset by reductions of operating lease liabilities of $90,000 , $14,000 of which relates to unrealized gains on foreign currency remeasurement associated with the operating lease liabilities. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: Nine Months Ended September 30, 2019 Operating Finance Weighted average remaining lease term (in years) 3.2 3.0 Weighted average discount rate 4.04% 4.00% Maturities of lease liabilities as of September 30, 2019 are as follows: (In thousands) Operating Finance 2019 (remaining 3 months) $ 28 $ 55 2020 113 220 2021 117 220 2022 114 170 2023 — 18 Total lease payments 372 683 Less imputed interest (23 ) (43 ) Present value of lease liabilities 349 640 Less current portion of lease liabilities (101 ) (196 ) Long-term portion of lease liabilities $ 248 $ 444
LEASES	LEASES The Company does not recognize leases with terms less than twelve months in duration in our consolidated balance sheet as right-of-use assets and lease liabilities. Leases with an initial term of 12 months or less or that have variable only payments are not recorded on the balance sheet. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's leases and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes a incremental borrowing rate of 4.00% , which is indicative of our collateralized borrowing rate. Operating Leases The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During Q2 2019, the Bulgaria facility lease was extended for an additional 2 years . In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. The Company's operating leases have terms expiring through December 2022. Finance Leases During August 2019, the Company entered into a non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. The Company's finance leases have terms expiring through August 2023. Information about the Company’s lease costs are as follows: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Lease costs (in thousands) : Operating lease costs $ 30 $ 85 Finance lease costs: Amortization of right-of-use assets 4 4 Interest on lease liabilities — — Variable lease costs 5 11 Total lease costs $ 39 $ 100 Cash and non cash information related to our leases are as follows: Nine Months Ended September 30, 2019 (in thousands) Operating Finance Non cash information: Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842 $ 212 $ — Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement $ 207 $ — Right-of-use assets capitalized and lease liabilities recognized upon execution of lease $ 20 $ 642 Cash information: Cash paid for lease liabilities $ 85 $ 12 Net, non cash lease expense of $2,000 for the nine months ended September 30, 2019 is comprised of reductions of operating right-of-use assets of $78,000 partially offset by reductions of operating lease liabilities of $90,000 , $14,000 of which relates to unrealized gains on foreign currency remeasurement associated with the operating lease liabilities. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: Nine Months Ended September 30, 2019 Operating Finance Weighted average remaining lease term (in years) 3.2 3.0 Weighted average discount rate 4.04% 4.00% Maturities of lease liabilities as of September 30, 2019 are as follows: (In thousands) Operating Finance 2019 (remaining 3 months) $ 28 $ 55 2020 113 220 2021 117 220 2022 114 170 2023 — 18 Total lease payments 372 683 Less imputed interest (23 ) (43 ) Present value of lease liabilities 349 640 Less current portion of lease liabilities (101 ) (196 ) Long-term portion of lease liabilities $ 248 $ 444

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories	Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours.
Recent Accounting Pronouncements	In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment will not have a material impact on our consolidated financial condition or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Topic 842 establishes a new lease model, referred to as the right-of-use model that brings substantially all leases on the balance sheet. This standard requires lessees to recognize leased assets and lease liabilities on the balance sheet and disclose key information about the leasing arrangements in their financial statements. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted Topic 842 effective January 1, 2019 using the modified retrospective transition approach that allows a reporting entity to use the effective date as its date of initial application and not restate the comparative periods in the period of adoption when transitioning to the new standard. Consequently, the requisite financial information and disclosures under the new standard are excluded for dates and periods prior to January 1, 2019. In addition, the Company elected to use a number of optional simplification and practical expedients permitted under the transition guidance within the new standard, including allowing the Company to combine fixed lease and non-lease components, apply the short-term lease exception to all leases of one year or less, and utilize the ‘package of practical expedients’, which permits the Company to not reassess prior accounting conclusions with respect to lease identification, lease classification and initial direct costs under Topic 842. Adoption of this new standard resulted in the recognition of approximately $212,000 of operating lease liabilities and right-of-user assets, which represents the present value of the remaining lease payments at the adoption date of approximately $221,000 , discounted using the Company’s incremental borrowing rate of 4.00% . Please see Note 13 for a full discussion of the impacts of adoption on the current year consolidated financial statements. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	A summary of the revisions as of each reporting period affected is as follows: As of and for the year ended December 31, 2018: (In thousands) As Reported Adjustments As Revised Balance Sheet Accrued severance and related $ 727 $ (117 ) $ 610 [1], [3] Additional paid-in capital 52,221 699 52,920 [1] Retained earnings 35,513 (582 ) 34,931 [1] Statement of Operations Professional services $ 3,072 $ 34 $ 3,106 [1] Salaries and related costs 8,673 548 9,221 [1] Loss per share from continuing operations Basic and Diluted $ (0.29 ) $ (0.01 ) $ (0.30 ) Income per share from discontinued operations Basic $ 2.21 $ — $ 2.21 Diluted $ 2.14 $ — $ 2.14 Income per share all operations Basic $ 1.93 $ (0.02 ) $ 1.91 Diluted $ 1.86 $ (0.01 ) $ 1.85 [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction [3] Financial statement caption has been condensed in accrued expenses and other liabilities in the current interim period As of and for the three months ended March 31, 2019: (In thousands) As Reported Adjustments As Revised Balance Sheet Other assets $ 162 $ 77 $ 239 [1] Contract liabilities — 194 194 [1] Additional paid-in capital 53,147 1,035 54,182 [1] Retained earnings 30,832 (1,152 ) 29,680 [1] Statement of Operations Sales $ 5,823 $ (194 ) $ 5,629 [2] Professional services 1,791 336 2,127 [1] Salaries and related costs 3,221 117 3,338 [1] Selling, general and administrative 3,101 (77 ) 3,024 [2] Loss per share - basic and diluted $ (0.14 ) $ (0.02 ) $ (0.16 ) [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction As of and for the six months ended June 30, 2019: (In thousands) As Reported Adjustments As Revised Balance Sheet Other assets $ 368 $ 77 $ 445 [1] Contract liabilities — 194 194 [1] Additional paid-in capital 54,051 1,035 55,086 [1] Retained earnings 26,494 (1,152 ) 25,342 [1] Statement of Operations Sales $ 12,391 $ (194 ) $ 12,197 [2] Professional services 3,424 336 3,760 [1] Salaries and related costs 6,554 117 6,671 [1] Selling, general and administrative 6,184 (77 ) 6,107 [2] Loss per share - basic and diluted $ (0.27 ) $ (0.02 ) $ (0.29 ) [1] Adjustments relate to stock-based compensation corrections [2] Adjustments relate to OEM revenue correction

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 6,126 $ 4,521 Finished goods and work-in-process 1,550 1,130 Gross inventories 7,676 5,651 Less: reserve for obsolescence (439 ) (439 ) Net inventories $ 7,237 $ 5,212

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, 2019 December 31, 2018 Accrued severance and related $ 235 $ 610 Accrued payroll 289 418 Accrued bonuses 936 972 Accrued commissions 784 379 Accrued legal and insurance 1,649 725 Other accrued expenses and current liabilities 3,392 3,058 Total accrued expenses and other current liabilities $ 7,285 $ 6,162

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Basic and diluted earnings per share	The following table provides the computation of basic and diluted earnings per share. Three Months Ended September, 30 Nine Months Ended (in thousands, except per share data) 2019 2018 2019 2018 Numerator: Net loss from continuing operations $ (4,311 ) $ (438 ) $ (13,900 ) $ (6,167 ) Net income from discontinued operations, net of tax $ — $ 69,612 $ — $ 74,134 Net income (loss) from all operations $ (4,311 ) $ 69,174 $ (13,900 ) $ 67,967 Denominator: Denominator - basic Weighted average shares outstanding - basic 33,942 33,275 33,903 33,014 Contingently issuable shares - basic 136 — 136 — Denominator - basic and diluted from continuing operations 34,078 33,275 34,039 33,014 Effect of dilutive securities: Stock options — 1,659 — 938 Denominator - diluted discontinued and all operations : 34,078 34,934 34,039 33,952 Loss per share from continuing operations: Basic and diluted $ (0.13 ) $ (0.01 ) $ (0.41 ) $ (0.19 ) Income per share from discontinued operations Basic $ — $ 2.09 $ — $ 2.25 Diluted $ — $ 1.99 $ — $ 2.19 Income (loss) per share from all operations Basic $ (0.13 ) $ 2.08 $ (0.41 ) $ 2.06 Diluted $ (0.13 ) $ 1.98 $ (0.41 ) $ 2.00 Anti-dilutive instruments excluded from diluted loss per common share: Restricted stock 90 — 90 — Options 4,060 — 4,060 —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of stock options and stock awards	The status of our stock options are summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2018 3,254,779 $ 3.18 Granted 1,379,500 7.70 Exercised (391,135 ) 2.84 Canceled and forfeited (183,500 ) 3.41 Outstanding at September 30, 2019 4,059,643 $ 4.73
Schedule of option fair value assumptions	2019 Grants Option value $ 7.15 - $ 7.91 Risk-free rate 1.7% - 2.6 % Expected dividend yield — Expected volatility 67.6% - 69.1 % Expected term (in years) 6

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Unrecognized tax benefits roll-forward	The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended September 30, 2019. (in thousands) Gross Unrealized Tax Benefits Balance at January 1, 2019 $ 1,313 Additions of tax positions related to the current year — Additions of tax positions related to the prior year — Decreases for tax positions related to the prior year — Balance at September 30, 2019 $ 1,313

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Marketable Securities at December 31, 2018: (In thousands) Adjusted Cost Unrealized Gains Fair Value (3) Cash and Cash Equivalents (1) Short-term Marketable Securities Cash $ 6,337 $ — $ 6,337 $ 6,337 $ — Level 1 (2) U.S. Treasury Securities, maturities less than three months 10,129 — 10,129 10,129 — U.S. Treasury Securities, maturities greater than three months 61,431 247 61,678 — 61,678 Total $ 77,897 $ 247 $ 78,144 $ 16,466 $ 61,678 (1) The Company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents. (2) The fair value of the debt securities consisting of U.S. Treasury bills is based on their quoted market prices. The fair value of these financial instruments are classified as Level 1 in the fair value hierarchy. The original purchase of U.S. Treasury bills occurred in September 2018, utilizing the proceeds from the sale of our Core business. (3) ASC 825-10 , Financial Instruments , allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings within interest income at each subsequent reporting date. At the date of purchase, the Company elected the fair value option for all investments with maturities of three months or greater at the time of purchase.

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2019 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 6,094 $ 1,481 $ — $ 7,575 Income (loss) from continuing operations (1,357 ) 268 (3,608 ) (4,697 ) Interest income — — 327 327 Other income, net — — 230 230 Income tax expense — — (171 ) (171 ) Three Months Ended September 30, 2018 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,985 $ 687 $ — $ 3,672 Income (loss) from continuing operations (1,155 ) 368 (2,009 ) (2,796 ) Interest income, net — — 105 105 Income tax benefit — — 2,408 2,408 Nine Months Ended September 30, 2019 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 15,734 $ 4,038 $ — $ 19,772 Income (loss) from continuing operations (5,756 ) 995 (10,174 ) (14,935 ) Interest income — — 1,153 1,153 Other income, net — — 5 5 Income tax expense — — (123 ) (123 ) Nine Months Ended September 30, 2018 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,727 $ 2,033 $ — $ 10,760 Income (loss) from continuing operations (2,525 ) 1,076 (7,000 ) (8,449 ) Interest income, net — — 33 33 Change in value of derivative liabilities — — 20 20 Income tax benefit — — 2,384 2,384
Schedule of revenue by geographic area	Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2019 2018 2019 2018 Sales by Domestic and International Domestic $ 5,552 $ 2,763 $ 14,002 $ 8,481 International 2,023 909 5,770 2,279 Total $ 7,575 $ 3,672 $ 19,772 $ 10,760

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Lease Costs	Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: Nine Months Ended September 30, 2019 Operating Finance Weighted average remaining lease term (in years) 3.2 3.0 Weighted average discount rate 4.04% 4.00% Information about the Company’s lease costs are as follows: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Lease costs (in thousands) : Operating lease costs $ 30 $ 85 Finance lease costs: Amortization of right-of-use assets 4 4 Interest on lease liabilities — — Variable lease costs 5 11 Total lease costs $ 39 $ 100 Cash and non cash information related to our leases are as follows: Nine Months Ended September 30, 2019 (in thousands) Operating Finance Non cash information: Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842 $ 212 $ — Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement $ 207 $ — Right-of-use assets capitalized and lease liabilities recognized upon execution of lease $ 20 $ 642 Cash information: Cash paid for lease liabilities $ 85 $ 12
Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of September 30, 2019 are as follows: (In thousands) Operating Finance 2019 (remaining 3 months) $ 28 $ 55 2020 113 220 2021 117 220 2022 114 170 2023 — 18 Total lease payments 372 683 Less imputed interest (23 ) (43 ) Present value of lease liabilities 349 640 Less current portion of lease liabilities (101 ) (196 ) Long-term portion of lease liabilities $ 248 $ 444
Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of September 30, 2019 are as follows: (In thousands) Operating Finance 2019 (remaining 3 months) $ 28 $ 55 2020 113 220 2021 117 220 2022 114 170 2023 — 18 Total lease payments 372 683 Less imputed interest (23 ) (43 ) Present value of lease liabilities 349 640 Less current portion of lease liabilities (101 ) (196 ) Long-term portion of lease liabilities $ 248 $ 444

BASIS OF PRESENTATION - NARRATI

BASIS OF PRESENTATION - NARRATIVE (Details) - USD ($) $ in Thousands	Aug. 30, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the disposition of Core business	$ 97,000		$ 0	$ 91,095
Manufacture and Supply Agreement | Symmetry Surgical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term	10 years
Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement | Symmetry Surgical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term	4 years
Manufacture and supply agreement	10 years
Discontinued Operations, Held-for-sale | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement | Symmetry Surgical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales		$ 2,500	6,900
Cost of sales		2,100	6,600
Operating expenses		$ 200	$ 300

BASIS OF PRESENTATION - Summary

BASIS OF PRESENTATION - Summary of Revisions (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Balance Sheet
Other assets	$ 387	$ 239		$ 445	$ 387		$ 305
Contract liabilities	339	194		194	339		0
Accrued severance and related	235				235		610
Additional paid-in capital	55,668	54,182		55,086	55,668		52,920
Retained earnings	21,031	29,680		25,342	21,031		34,931
Statement of Operations
Sales	7,575	5,629	$ 3,672	12,197	19,772	$ 10,760
Professional services	1,996	2,127	628	3,760	5,756	1,815	3,106
Salaries and related costs	3,020	3,338	2,119	6,671	9,691	5,734	$ 9,221
Selling, general and administrative	$ 3,762	$ 3,024	$ 1,957	$ 6,107	$ 9,869	$ 6,280
Loss per share from continuing operations
Basic and diluted (in dollars per share)	$ (0.13)	$ (0.16)	$ (0.01)	$ (0.29)	$ (0.41)	$ (0.19)	$ (0.30)
Income per share from discontinued operations
Basic (in dollars per share)	0		2.09		0	2.25	2.21
Diluted (in dollars per share)	0		1.99		0	2.19	2.14
Income per share all operations
Basic (in dollars per share)	(0.13)		2.08		(0.41)	2.06	1.91
Diluted (in dollars per share)	$ (0.13)		$ 1.98		$ (0.41)	$ 2	$ 1.85
Immaterial Corrections | As Reported
Balance Sheet
Other assets		$ 162		$ 368
Contract liabilities		0		0
Accrued severance and related							$ 727
Additional paid-in capital		53,147		54,051			52,221
Retained earnings		30,832		26,494			35,513
Statement of Operations
Sales		5,823		12,391
Professional services		1,791		3,424			3,072
Salaries and related costs		3,221		6,554			$ 8,673
Selling, general and administrative		$ 3,101		$ 6,184
Loss per share from continuing operations
Basic and diluted (in dollars per share)		$ (0.14)		$ (0.27)			$ (0.29)
Income per share from discontinued operations
Basic (in dollars per share)							2.21
Diluted (in dollars per share)							2.14
Income per share all operations
Basic (in dollars per share)							1.93
Diluted (in dollars per share)							$ 1.86
Immaterial Corrections | Adjustments
Balance Sheet
Other assets		$ 77		$ 77
Contract liabilities		194		194
Accrued severance and related							$ (117)
Additional paid-in capital		1,035		1,035			699
Retained earnings		(1,152)		(1,152)			(582)
Statement of Operations
Sales		(194)		(194)
Professional services		336		336			34
Salaries and related costs		117		117			$ 548
Selling, general and administrative		$ (77)		$ (77)
Loss per share from continuing operations
Basic and diluted (in dollars per share)		$ (0.02)		$ (0.02)			$ (0.01)
Income per share from discontinued operations
Basic (in dollars per share)							0
Diluted (in dollars per share)							0
Income per share all operations
Basic (in dollars per share)							(0.02)
Diluted (in dollars per share)							$ (0.01)

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 6,126	$ 4,521
Finished goods and work-in-process	1,550	1,130
Gross inventories	7,676	5,651
Less: reserve for obsolescence	(439)	(439)
Net inventories	$ 7,237	$ 5,212

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued severance and related	$ 235	$ 610
Accrued payroll	289	418
Accrued bonuses	936	972
Accrued commissions	784	379
Accrued legal and insurance	1,649	725
Other accrued expenses and current liabilities	3,392	3,058
Total accrued expenses and other current liabilities	$ 7,285	$ 6,162

RECENT ACCOUNTING PRONOUNCEME_2

RECENT ACCOUNTING PRONOUNCEMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right of use asset	$ 368
Lease liabilities	349
Operating lease remaining lease payments	$ 372	$ 221
Discount rate		4.00%
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right of use asset		$ 212
Lease liabilities		$ 212

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Numerator:
Net loss from continuing operations	$ (4,311)		$ (438)		$ (13,900)	$ (6,167)
Net income from discontinued operations, net of tax	0		69,612		0	74,134
Net income (loss)	$ (4,311)		$ 69,174		$ (13,900)	$ 67,967
Denominator:
Weighted average shares outstanding - basic (in shares)	33,942		33,275		33,903	33,014
Contingently issuable shares - basic (in shares)	136		0		136	0
Denominator - basic and diluted from continuing operations (in shares)	34,078		33,275		34,039	33,014
Stock options (in shares)	0		1,659		0	938
Denominator - basic and diluted (in shares)	34,078		34,934		34,039	33,952
Loss per share from continuing operations:
Basic and diluted (in dollars per share)	$ (0.13)	$ (0.16)	$ (0.01)	$ (0.29)	$ (0.41)	$ (0.19)	$ (0.30)
Income per share from discontinued operations
Basic (in dollars per share)	0		2.09		0	2.25	2.21
Diluted (in dollars per share)	0		1.99		0	2.19	2.14
Income (loss) per share from all operations
Basic (in dollars per share)	(0.13)		2.08		(0.41)	2.06	1.91
Diluted (in dollars per share)	$ (0.13)		$ 1.98		$ (0.41)	$ 2	$ 1.85
Restricted stock
Income (loss) per share from all operations
Anti-dilutive instruments excluded from diluted loss per common share (in shares)	90		0		90	0
Options
Income (loss) per share from all operations
Anti-dilutive instruments excluded from diluted loss per common share (in shares)	4,060		0		4,060	0

STOCK-BASED COMPENSATION - NARR

STOCK-BASED COMPENSATION - NARRATIVE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 543,000	$ 489,000	$ 2,594,000	$ 1,238,000
Shares surrendered in period (in shares)	26,572	532,477	118,170	576,135
Shares issued on net settlement of stock options (in shares)	34,928	680,388	220,879	713,980
Stock-based compensation expense to be recognized	$ 94,000		$ 94,000
Stock Option | 2019 Share Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares registered (in shares)	2,000,000		2,000,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants to date (in shares)	225,922		225,922
Shares vested to date (in shares)	135,555		135,555

STOCK-BASED COMPENSATION - SUMM

STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of options
Outstanding, beginning of period (in shares) | shares	3,254,779
Granted (in shares) | shares	1,379,500
Exercised (in shares) | shares	(391,135)
Canceled and forfeited (in shares) | shares	(183,500)
Outstanding, end of period (in shares) | shares	4,059,643
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 3.18
Granted (in dollars per share) | $ / shares	7.70
Exercised (in dollars per share) | $ / shares	2.84
Canceled and forfeited (in dollars per shares) | $ / shares	3.41
Outstanding, end of period (in dollars per share) | $ / shares	$ 4.73

STOCK-BASED COMPENSATION - FAIR

STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)	9 Months Ended
	Sep. 30, 2019$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value (in dollars per share)	$ 7.70
Expected dividend yield	0.00%
Expected volatility - low	67.60%
Expected volatility - high	69.10%
Expected term	6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value (in dollars per share)	$ 7.15
Risk-free rate	1.70%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value (in dollars per share)	$ 7.91
Risk-free rate	2.60%

INCOME TAXES - NARRATIVE (Detai

INCOME TAXES - NARRATIVE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 171,000	$ (2,408,000)	$ 123,000	$ (2,384,000)
Effective income tax rate, percent	(4.10%)	84.60%	(0.90%)	27.90%
Accrued interest and penalties	$ 197,000		$ 197,000
Interest and penalties included in income tax expense	146,000		197,000
Uncertain tax positions that would impact effective tax rate	$ 1,510,000		$ 1,510,000

INCOME TAXES - UNRECOGNIZED TAX

INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Gross Unrealized Tax Benefits
Balance at January 1, 2019	$ 1,313
Additions of tax positions related to the current year	0
Additions of tax positions related to the prior year	0
Decreases for tax positions related to the prior year	0
Balance at September 30, 2019	$ 1,313

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Apr. 17, 2019
Other Commitments [Line Items]
Purchase commitments	$ 4,600
Unfavorable Regulatory Action | Pending Litigation
Other Commitments [Line Items]
Costs accrued		$ 500

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Director - Bulgaria Manufacturing Plant Purchase $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Related Party Transaction [Line Items]
Notes payable	$ 140
Term of payment due	5 years

FINANCIAL INSTRUMENTS Narrative

FINANCIAL INSTRUMENTS Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Cash	$ 1,300	$ 6,337
US Treasury securities	$ 61,000

FINANCIAL INSTRUMENTS (Details)

FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Cash	$ 1,300	$ 6,337
Adjusted Cost		77,897
Unrealized Gains		247
Fair Value		78,144
Cash and cash equivalents	62,272	16,466
Short-term Marketable Securities	$ 0	61,678
U.S. Treasury Securities, maturities less than three months
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost		10,129
Fair Value		10,129
Cash equivalents		10,129
U.S. Treasury Securities, maturities greater than three months
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost		61,431
Unrealized Gains		247
Fair Value		61,678
Short-term Marketable Securities		$ 61,678

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting [Abstract]
Number of operating segments			2
International sales, percent of total revenue	26.70%	24.80%	29.20%	21.20%

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Sales	$ 7,575	$ 5,629	$ 3,672	$ 12,197	$ 19,772	$ 10,760
Income (loss) from continuing operations	(4,697)		(2,796)		(14,935)	(8,449)
Interest income	327		135		1,153	135
Interest income, net			105			33
Change in value of derivative liabilities	0		0		0	20
Other income, net	230		(155)		5	(155)
Income tax (expense) benefit	(171)		2,408		(123)	2,384
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	6,094		2,985		15,734	8,727
Income (loss) from continuing operations	(1,357)		(1,155)		(5,756)	(2,525)
Interest income	0				0
Interest income, net						0
Change in value of derivative liabilities						0
Other income, net	0				0
Income tax (expense) benefit	0		0		0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	1,481		687		4,038	2,033
Income (loss) from continuing operations	268		368		995	1,076
Interest income	0				0
Interest income, net						0
Change in value of derivative liabilities						0
Other income, net	0				0
Income tax (expense) benefit	0		0		0	0
Corporate & Other
Segment Reporting Information [Line Items]
Sales	0		0		0	0
Income (loss) from continuing operations	(3,608)		(2,009)		(10,174)	(7,000)
Interest income	327				1,153
Interest income, net			105			33
Change in value of derivative liabilities						20
Other income, net	230				5
Income tax (expense) benefit	$ (171)		$ 2,408		$ (123)	$ 2,384

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Sales	$ 7,575	$ 5,629	$ 3,672	$ 12,197	$ 19,772	$ 10,760
Domestic
Segment Reporting Information [Line Items]
Sales	5,552		2,763		14,002	8,481
International
Segment Reporting Information [Line Items]
Sales	$ 2,023		$ 909		$ 5,770	$ 2,279

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Lessee, Lease, Description [Line Items]
Discount rate	4.00%
Net, non cash lease expense	$ 2
Reduction of operating right-of-use assets	78
Reduction of operating lease liabilities	90
Unrealized gain on foreign currency remeasurement	$ 14
Sophia, Bulgaria
Lessee, Lease, Description [Line Items]
Term of contract	2 years

LEASES - Lease Costs (Details)

LEASES - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease costs	$ 30	$ 85
Amortization of right-of-use assets	4	4
Interest on lease liabilities	0	0
Variable lease costs	5	11
Total lease costs	$ 39	$ 100

LEASES - Cash and Non Cash Leas

LEASES - Cash and Non Cash Lease (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Operating
Cash paid for lease liabilities	$ 85
Finance
Cash paid for lease liabilities	12
ASU 2016-02
Operating
Right-of-use assets capitalized and lease liabilities	212
Finance
Right-of-use assets capitalized and lease liabilities	0
Lease Remeasurement
Operating
Right-of-use assets capitalized and lease liabilities	207
Finance
Right-of-use assets capitalized and lease liabilities	0
Lease Execution
Operating
Right-of-use assets capitalized and lease liabilities	20
Finance
Right-of-use assets capitalized and lease liabilities	$ 642

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details)	Sep. 30, 2019
Operating
Weighted average remaining lease term	3 years 2 months 12 days
Weighted average discount rate	4.04%
Finance
Weighted average remaining lease term	3 years
Weighted average discount rate	4.00%

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Operating
2019 (remaining 3 months)	$ 28
2020	113
2021	117
2022	114
2023	0
Total	372	$ 221
Less imputed interest	(23)
Present value of lease liabilities	349
Less current portion of lease liabilities	(101)
Long-term portion of lease liabilities	248
Finance Lease, Liability, Payment, Due [Abstract]
2019 (remaining 3 months)	55
2020	220
2021	220
2022	170
2023	18
Total lease payments	683
Less imputed interest	(43)
Present value of lease liabilities	640
Less current portion of lease liabilities	(196)
Long-term portion of lease liabilities	$ 444